GSK says heart drug darapladib fails in second late-stage trial
LONDON May 13 (Reuters) - GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.
Darapladib had already failed in a late-stage trial for patients with well-treated heart disease.
Patrick Vallance, GSK's President of Pharmaceuticals R&D, said he was disappointed that the outcome of the second phase III study did not support a regulatory submission.
"In the study, darapladib did not achieve the primary endpoint of a reduction of major coronary events versus placebo when added to standard of care," the British company said on Tuesday.
- Sierra Leone's chief Ebola doctor contracts the virus
- Gaza bloodshed deepens as airlines shun Israel |
- TransAsia Airways plane crashes in typhoon-hit Taiwan, killing 47
- Two Ukrainian fighter jets shot down over rebel-held territory
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand